Anemia and clinical outcomes in hepatitis C

This publication has 18 references indexed in Scilit:

• Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
  Gastroenterology, 2004
• Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection
  Journal of Viral Hepatitis, 2004
• Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3☆
  Gastroenterology, 2004
• Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
  Hepatology, 2003
• Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  Gastroenterology, 2002
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C
  Alimentary Pharmacology & Therapeutics, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001
• Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage
  Hepatology, 2000
• Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
  Hepatology, 1997